Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 5/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.36 |
| ▸ | BCL2 | P10415 | 3/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.31 |
| ▸ | PTGES | O14684 | 1/20 | 0.30 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.30 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 2/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22325185 | 1.00 | BCL2L1 (0.40) | BCL2L1PTGS2PTGS1BCL2SLC6A3 | |
| SCHEMBL26648644 | 0.91 | BCL2L1 (0.40) | BCL2L1PTGS2PTGS1BCL2SLC6A3 | |
| SCHEMBL22325211 | 0.91 | BCL2L1 (0.40) | BCL2L1PTGS2PTGS1BCL2SLC6A3 | |
| SCHEMBL1113744 | 0.85 | BCL2L1 (0.52) | BCL2L1PTGS2PTGS1BCL2SLC6A3 | |
| SCHEMBL30857688 | 0.80 | PTGS2 (0.41) | BCL2L1PTGS2PTGS1BCL2SLC6A3 | |
| SCHEMBL30857548 | 0.79 | BCL2L1 (0.34) | BCL2L1BCL2SLC6A3SLC6A2NOTUM | |
| SCHEMBL22325047 | 0.79 | BCL2L1 (0.34) | BCL2L1BCL2SLC6A3SLC6A2NOTUM | |
| SCHEMBL1701048 | 0.79 | BCL2L1 (0.37) | BCL2L1PTGS2PTGS1BCL2SLC6A3 | |
| SCHEMBL15538598 | 0.78 | PTGS2 (0.36) | BCL2L1PTGS2PTGS1BCL2SLC6A3 | |
| SCHEMBL1956706 | 0.76 | PTGS1 (0.51) | BCL2L1PTGS2PTGS1BCL2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260092057-A1 | BCL-XL/BCL-2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260092057-A1 | BCL-XL/BCL-2 DEGRADERS AND USES THEREOF | BCL2L2, BCL2A1, BCL2L1 | BCL2L1 3/4885PTGS2 178/4885PTGS1 197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.